Cue Health INC 8-K filings

Cue Health Inc. has filed for Chapter 7 bankruptcy, initiating a wind-down of its business after failing to secure additional financing or a strategic transaction.

Cue Health Inc. is experiencing significant challenges, including the resignation of two board members, an FDA warning letter leading to a temporary sales halt, and a delay in filing its quarterly report.

Cue Health Inc. has announced a significant cost reduction plan, including a 49% reduction in its global workforce, as part of a strategic shift to focus on its core technology.

Cue Health Inc. reports the resignation of its Chief Financial Officer, Aasim Javed, effective May 13, 2024, and the appointment of Randall Pollard as Principal Financial Officer on the same date.

Cue Health is exploring strategic options, including a potential sale, after the FDA indicated its RSV test does not meet the criteria for over-the-counter classification.

Cue Health Inc. has entered into a separation agreement with Mr. Khattak, who departed from the company on March 19, 2024.

Cue Health has appointed co-founder Clint Sever as CEO, succeeding Ayub Khattak, and added two strategic advisors to its board.

Cue Health reported a decrease in revenue for the fourth quarter and full year 2023, alongside significant cost reductions and strategic progress in product development and regulatory submissions.

Cue Health has entered into a cooperation agreement with Tarsadia Investments, appointing Rishi Reddy to its board of directors and planning to add another independent director.

Cue Health is implementing a new cost reduction plan that includes a 24% reduction in its global workforce, impacting 151 employees.